Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced a research study showing the potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro — specifically the Delta variant. The drug also reduces SARS-CoV-2-related lung injury in vivo and provides a strong rationale for trials of systemically delivered thiol drugs as coronavirus (COVID-19) treatments.
The study titled — ‘Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro’ — from the University of California, San Francisco (UCSF), also showed promising antiviral effects, the release said.
READ: Revive Therapeutics enters into research collaboration agreement for development of psilocybin microneedle patch
“We are excited to see another published paper supporting potent thiol drugs, like Bucillamine, for COVID-19, including the Delta variant, as we continue in our Phase 3 clinical study with Bucillamine to treat mild-to-moderate COVID-19. We are also gathering new scientific evidence to support Bucillamine’s potential for severe COVID-19,” said Michael Frank, CEO of Revive Therapeutics.
The Toronto-based biotech company said that it is currently exploring oral Bucillamine in Phase 3 clinical study to treat mild-to-moderate COVID-19.
Based on the published paper and the university work, the company will also seek to develop a reformulated version of Bucillamine as a potential treatment for severe COVID-19 disease and related infectious diseases.
Revive is focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the Food and Drugs Administration (FDA). With its acquisition of Psilocin Pharma Corp., Revive is also advancing the development of psilocybin-based therapeutics in various diseases and disorders.
Contact Ritika at ritika@proactiveinvestors.com